Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 106-115

  Muggia, Franco M ^a   Braly, Patricia S ^a   Brady, Mark F ^a   Sutton, Gregory ^a   Niemann, Theodore H ^a   Lentz, Samuel L ^a   Alvarez, Ronald D ^a   Kucera, Paul R ^a   Small, James M ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0033986363     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.106     Document Type: Article

References (28)

1. Omura GA, Blessing JA, Ehrlich CE, et al: A randomized trial of cyclophosphamide and adriamycin with and without cisplatin in advanced ovarian carcinoma: A Gynecology Oncology Group study. Cancer 57:1725-1730, 1986
2. Neijt JP, ten Bokkel Huinink WW, vander Burg ME, et al: Randomized trial comparing two combinations chemotherapy regimens (hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2:594-600, 1984
3. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factors analysis in advanced ovarian carcinoma: The Gynecology Group experience. J Clin Oncol 9:1138-1150, 1991
4. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Int Med 111:273-279 1989
5. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
6. McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial comparing cisplatin/cytoxan (CC) and cisplatin/Taxol (CT) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 12:255, 1993 (abstr 808)
7. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
8. Blessing JA: Design, analysis and interpretation of chemotherapy trials in gynecologic cancer, in Deppe G (ed): Chemotherapy of Gynecologic Cancer (ed 2). New York, NY, Alan R Liss Inc, 1990, pp 63-97
9. Makuch RW, Simon RM: Sample size requirements for comparing time-to-failure among k treatment groups. J Chron Dis 35:861-867, 1982
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Cox DR: Regression models and life-tables (with discussion), J Royal Stat Soc, Series B 34:187-220, 1972
12. Hess KR: Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 13:1045-1069, 1994
13. Conover WJ: Practical Nonparametric Statistics (ed 2). New York, NY, John Wiley and Sons, 1980
14. Dembo A: Controversy over combination chemotherapy in advanced ovarian cancer: What we learn from reports of matured data. J Clin Oncol 4:1573-1575, 1986
15. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. BMJ 303:884-893, 1991
16. Omura GA, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel at two dose levels and filgrastim at two doses in platinum pretreated epithelial ovarian cancer: A Gynecologic Oncology, SWOG, NCCTG, and ECOG study. Proc Am Soc Clin Oncol 15:A755, 1996 (abstr 755)
17. Stuart G, Bertelsen K, Mangioni C, et al: Updated analysis shows a highly significant overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-NOCOVA-NCI-C and Scottish intergroup trial. Proc Am Soc Clin Oncol 17:361A, 1998 (abstr 1394)
18. Conte PF, Bruzzone M, Carino F, et al: High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorusbicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14:351-356, 1996
19. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecology Oncology Group study. J Clin Oncol 13:1589-1599, 1995
20. Colombo N, Pittelli MR, Marzola M, et al: Randomized study of two cisplatin dose-intensity regimens in patients with stage III/IV epithelial ovarian cancer. Proc Am Soc Clin Oncol 9:160, 1990 (abstr 619)
21. Kaye SB, Paul J, Cassidy J, et al: Mature results for a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113-2119, 1996
22. Perren TJ, Wiltshaw E, Harper P, et al: A randomized study of carboplatin vs. sequential ifosfamide/carboplatinum for patients with FIGO stage III epithelial ovarian carcinoma. Br J Cancer 68:1190-1194, 1993
23. Wiltshaw E, Evans B, Rustin G, et al: A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 4:722-729, 1986
24. Gruppo Interregionale Cooperativo Oncologico Ginecologia: Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987
25. Bolis G, Favalli G, Danese S, et al: Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J Clin Oncol 15:1938-1944, 1997
26. Neijt JP, Hansen M, Hansen SW, et al: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 16:352, 1997 (abstr 1259)
27. st-line treatment in ovarian cancer. Proc Am Soc Clin Oncol 17:361, 1998 (abstr 1395)
28. Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecology Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 18:356A, 1999 (abstr 1373)